Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Betterlife Pharma Inc (CSE: BETR )

0.1200 UNCHANGED
Streaming Delayed Price Updated: 1:41 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Betterlife Pharma Inc

< Previous 1 2 Next >
BetterLife Obtains Favourable Genotoxicity Data for Oral BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Announces Fully Subscribed Private Placement Financing
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Highlights Advantages of Non-hallucinogenic LSD Derivative BETR-001 and Publication of its Methods to Treat Mood Disorders Patent
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Announces Closing of a Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife To Present BETR-001 Preclinical Data at the 2024 Conference of the Federation of European Neuroscience Societies (FENS) in Vienna, Austria
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Announces Closing of a Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Announces Intent to Complete Private Placement of Units
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Advances BETR-001 IND-enabling Studies
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Announces Closing of a Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Announces Extension of Warrants
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Pharma to Host Investors Update Call on September 18, 2023
From BetterLife Pharma Inc.
Via GlobeNewswire
US Patent and Trademark Office Publishes BetterLife’s Comprehensive Patent for BETR-001 and Other LSD Derivatives
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces Closing of a Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
Better Home & Finance Announces Closing of Business Combination
From Better Home & Finance
Via Business Wire
BetterLife Highlights American College of Physicians’ Updated Guidelines for Treating Depression and Announces Closing of Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Continues Progress on BETR-001 IND-Enabling Studies
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article
From BetterLife Pharma Inc.
Via GlobeNewswire
Promise of BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article
From BetterLife Pharma Inc.
Via GlobeNewswire
Betterlife Publishes Promising Results from a Study Titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders”
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments
From BetterLife Pharma Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.